Principal Financial Group
EWTX icon

Principal Financial Group’s Edgewise Therapeutics EWTX Stock Holding History

Principal Financial Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,084
Closed -$236K – 2288
2024
Q2 		$236K Sell
13,084
-3,681
-22% -$64.2K ﹤0.01% 2112
2024
Q1 		$306K Buy
16,765
+365
+2% +$5.8K ﹤0.01% 2084
2023
Q4 		$179K Sell
16,400
-1,161
-7% -$8.15K ﹤0.01% 2187
2023
Q3 		$101K Buy
17,561
+1,479
+9% +$10.1K ﹤0.01% 2281
2023
Q2 		$125K Buy
16,082
+3,904
+32% +$32.9K ﹤0.01% 2256
2023
Q1 		$81.2K Buy
12,178
+1,230
+11% +$11.4K ﹤0.01% 2327
2022
Q4 		$97.9K Buy
+10,948
New +$103K ﹤0.01% 2297

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Principal Financial Group's EWTX Position: Q3 2024 in Review

Principal Financial Group sold out of Edgewise Therapeutics (EWTX) in Q3 2024, closing a stake of 13,084 shares — an estimated $236K sold.

Principal Financial Group first reported a position in EWTX in Q4 2022 and held it in 7 quarters. The position peaked at $306K in Q1 2024. 177 funds tracked by Wall St. Rank hold EWTX as of Q3 2024.

  • Principal Financial Group reported no remaining Edgewise Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 13,084 Edgewise Therapeutics shares in Q3 2024, an estimated $236K.
  • Principal Financial Group first reported a position in Edgewise Therapeutics in Q4 2022 and held it in 7 quarters.
  • Principal Financial Group's Edgewise Therapeutics position peaked at $306K in Q1 2024.
  • 177 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.